Development of balanced dual PI3K/mTOR kinase inhibitors: A new generation of potential drugs for targeted cancer therapy (solid tumors)

• Unité de recherche: INNOSUISSE
• Numéro de projet: 14032.1;10 PFLS-LS
• Titre du projet anglais: Development of balanced dual PI3K/mTOR kinase inhibitors: A new generation of potential drugs for targeted cancer therapy (solid tumors)

Description succincte (Allemand)

Development of balanced dual PI3K/mTOR kinase inhibitors: A new generation of potential drugs for targeted cancer therapy (solid tumors)

Description succincte (Anglais)

Development of balanced dual PI3K/mTOR kinase inhibitors: A new generation of potential drugs for targeted cancer therapy (solid tumors)

Résumé des résultats (Abstract) (Allemand)

The proposed CTI project aims to develop PI3K/mTOR kinase inhibitors as a new generation of drugs for the treatment of solid tumors such as pancreatic cancer. The designed approach allows discovery and development of lipid-modifying enzyme inhibitors. The methodology and the products complement the existing PIQUR technology portfolio, and open a new branch of commercial opportunities. The project is expected to support current PIQUR activities by identifying a best-in-class clinical candidate, which in comparison with the competitor compounds of same mode of action, has a balanced dual PI3K/mTOR inhibition and improved pharmacological properties, providing optimal therapies, tailored to the unique needs of solid tumors.

Résumé des résultats (Abstract) (Anglais)

The proposed CTI project aims to develop PI3K/mTOR kinase inhibitors as a new generation of drugs for the treatment of solid tumors such as pancreatic cancer. The designed approach allows discovery and development of lipid-modifying enzyme inhibitors. The methodology and the products complement the existing PIQUR technology portfolio, and open a new branch of commercial opportunities. The project is expected to support current PIQUR activities by identifying a best-in-class clinical candidate, which in comparison with the competitor compounds of same mode of action, has a balanced dual PI3K/mTOR inhibition and improved pharmacological properties, providing optimal therapies, tailored to the unique needs of solid tumors.